The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Marketwire

ProMetic to Report its Fourth Quarter and Year End 2012 Financial Results and Hold Conference Call/Webcast

Tuesday, March 19, 2013

ProMetic to Report its Fourth Quarter and Year End 2012 Financial Results and Hold Conference Call/Webcast12:03 EDT Tuesday, March 19, 2013LAVAL, QUEBEC--(Marketwire - March 19, 2013) -ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic" or the "Corporation") today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2012 on Tuesday, March 26, 201 3 after market trading hours.ProMetic will host a conference call at 11:00am (EDT) on Wednesday, March 27, 2013. The telephone numbers to access the conference call are (416) 981-9000 (International) and 1-800-755-1805 (North America Toll-Free). A live audio webcast of the conference call will be available via http://www.gowebcasting.com/4228An audio replay of the call will be available for a period of seven days as of Wednesday March 27, 2013, at 1:30pm (EDT). The numbers to access the audio replay are (416) 626-4100 (international) and 1 (800) 558-5253 (North America Toll Free) using access code: 21652529. About ProMetic Life Sciences Inc. ProMetic Life Sciences Inc. ("ProMetic") (www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Laval (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia.FOR FURTHER INFORMATION PLEASE CONTACT: Contact Information: Pierre LaurinPresident and CEOProMetic Life Sciences Inc.p.laurin@prometic.com450.781.0115Frederic DumaisDirector, Communications andInvestor RelationsProMetic Life Sciencesf.dumais@prometic.com450-781-0115